132 related articles for article (PubMed ID: 8117411)
1. Serum alpha 1-antichymotrypsin is not a useful marker for Alzheimer's disease or dementia in Parkinson's disease.
Kuiper MA; van Kamp GJ; Bergmans PL; Scheltens P; Wolters EC
J Neural Transm Park Dis Dement Sect; 1993; 6(2):145-9. PubMed ID: 8117411
[TBL] [Abstract][Full Text] [Related]
2. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease.
Pirttila T; Mehta PD; Frey H; Wisniewski HM
Neurobiol Aging; 1994; 15(3):313-7. PubMed ID: 7936055
[TBL] [Abstract][Full Text] [Related]
3. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia.
Matsubara E; Hirai S; Amari M; Shoji M; Yamaguchi H; Okamoto K; Ishiguro K; Harigaya Y; Wakabayashi K
Ann Neurol; 1990 Oct; 28(4):561-7. PubMed ID: 2147546
[TBL] [Abstract][Full Text] [Related]
4. Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia.
Lieberman J; Schleissner L; Tachiki KH; Kling AS
Neurobiol Aging; 1995; 16(5):747-53. PubMed ID: 8532107
[TBL] [Abstract][Full Text] [Related]
5. Relationship between serum alpha 1-antichymotrypsin and Alzheimer's disease.
Hinds TR; Kukull WA; Van Belle G; Schellenberg GD; Villacres EC; Larson EB
Neurobiol Aging; 1994; 15(1):21-7. PubMed ID: 8159260
[TBL] [Abstract][Full Text] [Related]
6. Serum concentration of alpha 1-antichymotrypsin is elevated in patients with senile dementia of the Alzheimer type.
Matsubara E; Amari M; Shoji M; Harigaya Y; Yamaguchi H; Okamoto K; Hirai S
Prog Clin Biol Res; 1989; 317():707-14. PubMed ID: 2690117
[TBL] [Abstract][Full Text] [Related]
7. [Serum alpha 1-antichymotrypsin in senile dementia].
Nagao T; Hamamoto M; Hagiwara M; Kanda A; Ichiseki H; Miyazaki T; Isse K; Tanaka K; Ogura M; Tsushima T
Nihon Ronen Igakkai Zasshi; 1992 Oct; 29(10):778-82. PubMed ID: 1460783
[TBL] [Abstract][Full Text] [Related]
8. Serological alpha 1-antichymotrypsin in patients with probable senile dementia of Alzheimer type: a short-term longitudinal study.
Licastro F; Davis LJ; Polazzi E; Rossi S; Cucinotta D
Alzheimer Dis Assoc Disord; 1996; 10(4):192-6. PubMed ID: 8939278
[TBL] [Abstract][Full Text] [Related]
9. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.
DeKosky ST; Ikonomovic MD; Wang X; Farlow M; Wisniewski S; Lopez OL; Becker JT; Saxton J; Klunk WE; Sweet R; Kaufer DI; Kamboh MI
Ann Neurol; 2003 Jan; 53(1):81-90. PubMed ID: 12509851
[TBL] [Abstract][Full Text] [Related]
10. Increased chemiluminescence response of neutrophils from the peripheral blood of patients with senile dementia of the Alzheimer's type.
Licastro F; Morini MC; Davis LJ; Malpassi P; Cucinotta D; Parente R; Melotti C; Savorani G
J Neuroimmunol; 1994 Apr; 51(1):21-6. PubMed ID: 8157733
[TBL] [Abstract][Full Text] [Related]
11. Serological alpha 1-antichymotrypsin in Down's syndrome and Alzheimer's disease.
Brugge K; Katzman R; Hill LR; Hansen LA; Saitoh T
Ann Neurol; 1992 Aug; 32(2):193-7. PubMed ID: 1387300
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E4 serum concentration for increased sensitivity and specificity of diagnosis of drug treated Alzheimer's disease patients vs. drug treated parkinson's disease patients vs. age-matched normal controls.
Goldknopf IL; Park HR; Sabbagh M
Curr Alzheimer Res; 2012 Dec; 9(10):1149-67. PubMed ID: 22950864
[TBL] [Abstract][Full Text] [Related]
13. Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target.
Porcellini E; Davis EJ; Chiappelli M; Ianni E; Di Stefano G; Forti P; Ravaglia G; Licastro F
Curr Pharm Des; 2008; 14(26):2659-64. PubMed ID: 18991685
[TBL] [Abstract][Full Text] [Related]
14. Blood levels of alpha-1-antichymotrypsin and risk factors for Alzheimer's disease: effects of gender and apolipoprotein E genotype.
Licastro F; Masliah E; Pedrini S; Thal LJ
Dement Geriatr Cogn Disord; 2000; 11(1):25-8. PubMed ID: 10629358
[TBL] [Abstract][Full Text] [Related]
15. Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response.
Licastro F; Morini MC; Polazzi E; Davis LJ
J Neuroimmunol; 1995 Mar; 57(1-2):71-5. PubMed ID: 7535791
[TBL] [Abstract][Full Text] [Related]
16. Elevated alpha 1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients.
Altstiel LD; Lawlor B; Mohs R; Schmeidler J; Dalton A; Mehta P; Davis K
Dementia; 1995; 6(1):17-20. PubMed ID: 7728215
[TBL] [Abstract][Full Text] [Related]
17. Monomeric and polymeric forms of alpha-1 antichymotrypsin in sera from patients with probable late onset Alzheimer's disease.
Licastro F; Sirri V; Trerè D; Davis LJ
Dement Geriatr Cogn Disord; 1997; 8(6):337-42. PubMed ID: 9370085
[TBL] [Abstract][Full Text] [Related]
18. Erythrocyte thiolmethyltransferase: another failed marker for Alzheimer's and Parkinson's diseases.
Hurwitz A; Hubble JP; Glatt SL; Koller WC; Pollack J
Neurology; 1995 Oct; 45(10):1903-6. PubMed ID: 7477990
[TBL] [Abstract][Full Text] [Related]
19. Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease.
de la Monte SM; Wells SE; Hedley-Whyte T; Growdon JH
Ann Neurol; 1989 Sep; 26(3):309-20. PubMed ID: 2802531
[TBL] [Abstract][Full Text] [Related]
20. Combination of serum markers related to several mechanisms in Alzheimer's disease.
Teunissen CE; Lütjohann D; von Bergmann K; Verhey F; Vreeling F; Wauters A; Bosmans E; Bosma H; van Boxtel MP; Maes M; Delanghe J; Blom HJ; Verbeek MM; Rieckmann P; De Bruijn C; Steinbusch HW; de Vente J
Neurobiol Aging; 2003 Nov; 24(7):893-902. PubMed ID: 12928047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
